Gonadorelin Acetate (2mg)

Gonadorelin Acetate (2mg): The Acetate Salt Form of Synthetic Human Gonadotropin-Releasing Hormone (GnRH/LHRH) — a Decapeptide That Serves as the Master Regulator of the Hypothalamic-Pituitary-Gonadal (HPG) Axis, Stimulating Pulsatile Release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) to Regulate Testosterone, Spermatogenesis, Ovulation, Estrogen/Progesterone, and Reproductive Function — the 2mg Vial Format (Acetate Salt for Enhanced Solubility and Stability) for Investigational Research in Reproductive Endocrinology, Hypogonadism, Fertility, and HPG Axis Modulation

Gonadorelin acetate is the acetate salt form of synthetic human gonadotropin-releasing hormone (GnRH, also known as luteinizing hormone-releasing hormone [LHRH] or luteinizing hormone-releasing factor [LRF]) — a decapeptide (ten-amino-acid peptide) with the sequence pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (pGlu = pyroglutamic acid, a cyclized form of glutamic acid at the N-terminus that confers metabolic stability by resisting aminopeptidase degradation; the C-terminal glycine is amidated, which is important for receptor binding and biological activity). The acetate salt form means that the peptide is formulated with acetic acid (typically 1-3 acetate molecules per peptide molecule) to neutralize the positively charged amino groups on the peptide (particularly the arginine residue and the N-terminal amino group, although the N-terminus is pyroglutamylated so the primary positive charges are on arginine and possibly histidine), resulting in a salt that has enhanced water solubility, improved stability (both in lyophilized form and in solution), and more consistent dosing compared to the free base or trifluoroacetate (TFA) salt forms. Acetate salts are generally preferred for pharmaceutical and research peptide formulations because acetate is an endogenous, physiologically compatible anion (acetic acid is a normal metabolic intermediate in the body, produced by cellular metabolism and found at low concentrations in blood and tissues), it is generally recognized as safe (GRAS), it does not accumulate in the body (it is rapidly metabolized), and it typically produces less irritation at injection sites compared to some other salt forms (such as TFA, which is a stronger acid and can cause more injection site irritation). Gonadorelin acetate is biologically identical to native GnRH (the acetate counterion does not affect the peptide's receptor binding or biological activity — it is simply a formulation choice for solubility and stability), and it exerts the same physiological effects: it is produced (endogenously) by specialized neuroendocrine neurons (~800-1000 GnRH neurons in the human hypothalamus, primarily in the preoptic area and arcuate nucleus) that project to the median eminence, where GnRH is released in discrete pulses (every 60-120 minutes in adult humans) into the hypophyseal portal circulation — a specialized vascular system directly connecting the hypothalamus to the anterior pituitary, allowing hypothalamic hormones to reach the pituitary at high concentrations without systemic dilution. When GnRH binds to its receptor (GnRHR, a class A G-protein-coupled receptor of the rhodopsin-like family, expressed on gonadotroph cells constituting ~10-15% of anterior pituitary cells), it activates the Gq/11 signaling pathway (phospholipase C → inositol trisphosphate → intracellular calcium mobilization, plus diacylglycerol → protein kinase C), triggering the synthesis and release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH and FSH regulate gonadal function: in males, LH stimulates Leydig cells to produce testosterone (the primary male sex hormone, responsible for secondary sexual characteristics, libido, muscle mass, bone density, and spermatogenesis support), while FSH stimulates Sertoli cells to support spermatogenesis (sperm production) and produce inhibin B (which provides negative feedback to suppress FSH); in females, LH stimulates theca cells to produce androgens (converted to estrogens by granulosa cells), triggers ovulation (the mid-cycle LH surge is the direct trigger for ovulation), and stimulates the corpus luteum to produce progesterone after ovulation, while FSH stimulates granulosa cells in ovarian follicles to promote follicular growth and maturation, produce estradiol (the primary estrogen), and produce inhibin B. The HPG axis is regulated by elegant negative (and, in females, pre-ovulatory positive) feedback loops: testosterone/estradiol provide negative feedback at both the hypothalamus (reducing GnRH pulse frequency) and pituitary (reducing LH responsiveness to GnRH); inhibin B selectively suppresses FSH; and in females, high pre-ovulatory estradiol switches from negative to positive feedback, stimulating the GnRH/LH surge that triggers ovulation — a rare example of positive feedback in physiology. The defining feature of GnRH physiology — and the critical consideration for anyone working with gonadorelin acetate — is that GnRH MUST be administered in a PULSATILE fashion (discrete pulses every 60-120 minutes) to stimulate the HPG axis. This was definitively demonstrated in the landmark 1978 study by Belchetz and colleagues, who showed that continuous infusion of GnRH caused rapid desensitization and down-regulation of GnRH receptors on pituitary gonadotrophs, leading to paradoxical SUPPRESSION of LH and FSH release, while pulsatile GnRH (one pulse per hour) maintained and stimulated normal LH/FSH release. This dual nature — stimulatory when pulsatile, suppressive when continuous — is the fundamental principle that explains both the therapeutic use of native pulsatile GnRH (to stimulate the HPG axis in hypogonadotropic hypogonadism and infertility) and the mechanism of action of GnRH agonist drugs (leuprolide, goserelin, triptorelin — modified analogues with increased receptor affinity and metabolic stability that, when administered continuously via depot injection, cause desensitization and suppression, therapeutically useful for prostate cancer, endometriosis, uterine fibroids, precocious puberty, and assisted reproduction). Gonadorelin acetate has been used clinically and in research for several decades, with applications including: (1) Diagnostic testing — the GnRH stimulation test (gonadorelin test), in which a single IV or SC dose (typically 100 mcg in adults, 2.5-3 mcg/kg in children) is administered and LH/FSH measured at 0, 15, 30, 60, 90 minutes to assess pituitary gonadotroph function and distinguish hypothalamic (normal pituitary response — hypogonadism due to GnRH deficiency) from pituitary (blunted/absent response — hypopituitarism) causes of hypogonadotropic hypogonadism, evaluate delayed vs. permanent hypogonadism in adolescents, and distinguish central (GnRH-dependent, adult-like LH response) from peripheral (GnRH-independent, prepubertal response) precocious puberty; (2) Therapeutic — pulsatile GnRH for hypogonadotropic hypogonadism and infertility — in Kallmann syndrome (hypogonadotropic hypogonadism with anosmia, caused by failed GnRH neuron migration during embryogenesis), idiopathic hypogonadotropic hypogonadism (IHH), functional hypothalamic amenorrhea (excessive exercise/stress/low body weight in women), hyperprolactinemia-induced hypogonadism, and hypothalamic/pituitary tumors or their treatment, pulsatile GnRH via programmable subcutaneous infusion pump (5-20 mcg pulses every 60-120 minutes) can restore normal LH/FSH, gonadal hormones, spermatogenesis (men), and ovulation/menstrual cycles (women) — the most physiological approach to hypothalamic hypogonadism, often more effective for fertility than exogenous testosterone or gonadotropins; (3) Therapeutic — ovulation trigger in IVF — in GnRH antagonist IVF protocols, a GnRH agonist (including native GnRH/gonadorelin) can trigger an endogenous LH surge for final oocyte maturation instead of hCG, dramatically reducing ovarian hyperstimulation syndrome (OHSS) risk due to the much shorter half-life of endogenous LH (~20-30 min) vs. hCG (~24-36 hr); (4) Research applications — HPG axis physiology, GnRH receptor biology/signaling/desensitization, pulsatile hormone secretion patterns, hypogonadism/infertility (male and female), puberty disorders, sexual function/libido, bone metabolism, body composition, aging/reproductive aging, and GnRH analogue drug development. The 2mg vial format of research-grade gonadorelin acetate is well-suited for smaller-scale research, pilot studies, and protocols requiring precise, lower-dose administration: at typical pulsatile doses of 5-20 mcg per pulse, a 2mg vial provides 100-400 pulses; at diagnostic stimulation test doses of 100-500 mcg per test, it provides 4-20 tests. Reconstitution: add 1-5 mL of bacteriostatic water (or sterile water for IV use) to yield 2-0.4 mg/mL; for example, adding 2 mL yields 1 mg/mL (1000 mcg/mL), so a 5 mcg pulse = 0.005 mL, 10 mcg = 0.01 mL, 20 mcg = 0.02 mL, 100 mcg = 0.1 mL, 500 mcg = 0.5 mL. Reconstituted gonadorelin acetate is stable for 7-14 days when refrigerated at 4°C and protected from light; the lyophilized powder is stable for 24 months from manufacture when stored at -20°C, protected from light and moisture. The safety profile is generally favorable (as an endogenous hormone), with common side effects being mild injection site reactions (erythema, swelling, pain — generally less with acetate than TFA salt), occasional headache, nausea, flushing; with pulsatile ovulation induction, monitor for ovarian hyperstimulation (ultrasound + estradiol); rare allergic reactions. CRITICAL: continuous (non-pulsatile) administration causes GnRH receptor desensitization/down-regulation → HPG axis SUPPRESSION (low LH/FSH, low testosterone/estradiol, hot flashes, decreased libido, erectile dysfunction, menstrual irregularity, bone loss with long-term use) — this is the intended effect of GnRH agonists but is an adverse effect if stimulation was intended; ALWAYS use pulsatile administration (infusion pump or timed q60-120 min injections) if the goal is HPG stimulation. As of 2026, gonadorelin acetate is available as a prescription pharmaceutical in many countries (for diagnostic and therapeutic use), and the research-grade gonadorelin acetate supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

The Acetate Salt Advantage, Gonadorelin Acetate in Clinical and Research Practice, and the 2mg Vial Format

The choice of salt form is an important consideration in peptide formulation, and the acetate salt offers several advantages that make gonadorelin acetate the preferred form for most pharmaceutical and research applications. To understand the acetate salt advantage, it is first necessary to understand why peptides are formulated as salts at all: peptides contain multiple ionizable groups — the N-terminal amino group (although in GnRH the N-terminus is pyroglutamylated, so it is not ionizable), the C-terminal carboxyl group (although in GnRH the C-terminus is amidated, so it is also not ionizable), and the side chains of amino acids with ionizable groups (in GnRH, the arginine residue at position 8 has a positively charged guanidino group with a pKa of ~12.5, and the histidine residue at position 2 has an imidazole side chain with a pKa of ~6.0 that can be partially protonated at physiological pH). These positively charged groups make the peptide a cation (base) in solution, and to form a stable, crystalline, water-soluble solid, the peptide is typically neutralized with an acid to form a salt. The most common salt forms for peptides are: (1) Acetate salt — formed by neutralizing the peptide with acetic acid (CH3COOH), resulting in acetate (CH3COO-) as the counterion; this is the most common and preferred salt form for pharmaceutical peptides because acetate is an endogenous, physiologically compatible anion (acetic acid is a normal metabolic intermediate, produced by cellular metabolism — particularly anaerobic glycolysis and fatty acid synthesis — and found at low concentrations [~0.1-0.5 mM] in blood and tissues), it is generally recognized as safe (GRAS) by regulatory agencies, it does not accumulate in the body (it is rapidly metabolized by the liver and other tissues through the citric acid cycle and other pathways), it typically produces less irritation at injection sites compared to stronger acid salts, and acetate salts generally have good water solubility and stability; (2) Trifluoroacetate (TFA) salt — formed by neutralizing with trifluoroacetic acid (CF3COOH), a strong acid commonly used in peptide synthesis purification (HPLC); TFA salts are often the default form produced during peptide synthesis and purification, but they have several disadvantages for pharmaceutical/research use: TFA is a stronger acid than acetic acid and can cause more injection site irritation (pain, erythema, induration), TFA is not an endogenous compound and there have been some concerns about potential toxicity of residual TFA (although the amounts in typical peptide doses are generally considered safe), TFA salts may have different solubility and stability characteristics compared to acetate, and regulatory agencies generally prefer acetate over TFA for pharmaceutical formulations; (3) Hydrochloride (HCl) salt — formed with hydrochloric acid; less common for peptides, can cause injection irritation; (4) Citrate, tartrate, and other organic acid salts — used for specific formulations where particular solubility or stability characteristics are desired. For gonadorelin specifically, the acetate salt offers the following practical advantages: (a) Enhanced water solubility — gonadorelin acetate is readily soluble in water and bacteriostatic water at the concentrations typically used for reconstitution (0.4-2 mg/mL), whereas the free base may have lower solubility and the TFA salt may have variable solubility depending on the degree of TFA substitution; (b) Improved stability — acetate salts generally have good stability both in lyophilized form (24 months at -20°C) and in reconstituted solution (7-14 days at 4°C), with the acetate counterion providing a slightly acidic microenvironment that can help protect the peptide from degradation; (c) Reduced injection site irritation — because acetate is a weaker acid and a physiologically compatible endogenous anion, gonadorelin acetate injections are generally better tolerated than TFA salt injections, with less pain, erythema, and induration at the injection site — this is particularly important for pulsatile GnRH therapy, where the peptide is administered via subcutaneous infusion pump with continuous or repeated needle placement; (d) Consistent dosing — acetate salts typically have well-defined stoichiometry (a known number of acetate molecules per peptide molecule, typically 1-3 for GnRH depending on the degree of protonation), which allows for more accurate and consistent dosing compared to free base or TFA salts where the degree of salt formation may be more variable; (e) Regulatory and pharmaceutical acceptance — acetate is the preferred salt form for most pharmaceutical peptides, and gonadorelin acetate is the form used in most approved pharmaceutical products (e.g., Factrel, Lutrepulse, Crystodur), making it the standard for clinical and research use. In clinical and research practice, gonadorelin acetate is used in several well-established protocols: (1) GnRH stimulation test (diagnostic) — the most common diagnostic use; protocol: after an overnight fast (or at least 4 hours without food), an IV catheter is placed, baseline blood samples are drawn for LH, FSH, and sometimes testosterone/estradiol, then 100 mcg of gonadorelin acetate is administered as an IV bolus (or SC injection in some protocols), and blood samples are drawn at 15, 30, 60, and 90 minutes for LH and FSH measurement; interpretation: normal response = LH rises 2-5× baseline (peak at 15-30 min), FSH rises 1.5-2× (peak at 30-60 min); exaggerated response = primary gonadal failure (Klinefelter, Turner, premature ovarian insufficiency); blunted/absent response = pituitary dysfunction (hypopituitarism); in children with delayed puberty, a prepubertal/early pubertal response suggests constitutional delay, while an absent/blunted response suggests permanent hypogonadotropic hypogonadism; in precocious puberty, an adult-like LH-dominant response (LH peak >5-10 IU/L, LH:FSH ratio >1) suggests central precocious puberty, while a prepubertal FSH-dominant response suggests peripheral precocious puberty; (2) Pulsatile GnRH therapy (therapeutic) — used for hypogonadotropic hypogonadism and infertility; protocol: a programmable subcutaneous infusion pump (similar to an insulin pump) is placed, typically delivering 5-20 mcg of gonadorelin acetate per pulse (the dose may be adjusted based on LH/FSH response and gonadal hormone levels), with one pulse every 60-120 minutes (the pulse frequency may be adjusted — faster pulses [60 min] favor LH secretion, slower pulses [120 min] favor FSH secretion, and in women the pulse frequency may be adjusted across the menstrual cycle to mimic natural physiology); therapy is continued 24 hours a day, with regular monitoring of LH, FSH, testosterone/estradiol, and (in women) ultrasound follicle monitoring; in men, pulsatile GnRH can induce spermatogenesis (often achieving sperm counts sufficient for natural conception within 6-18 months, although the response may be slower in patients with long-standing hypogonadism or prior testosterone therapy); in women, pulsatile GnRH can induce ovulation and regular menstrual cycles, with pregnancy rates of 70-90% in appropriately selected patients (comparable to or better than gonadotropin therapy, with a lower risk of multiple pregnancy and ovarian hyperstimulation); (3) GnRH agonist trigger for ovulation (IVF/ART) — in IVF protocols using GnRH antagonists (which suppress endogenous LH without causing the prolonged desensitization seen with agonists), a single dose of a GnRH agonist (including native gonadorelin acetate at 0.5-1 mg, or a potent agonist like triptorelin at 0.2-0.5 mg) is administered to trigger an endogenous LH surge for final oocyte maturation, instead of the traditional hCG trigger (5,000-10,000 IU); because the endogenous LH surge has a much shorter half-life (~20-30 minutes for LH vs. ~24-36 hours for hCG), the GnRH agonist trigger is associated with a dramatically lower risk of ovarian hyperstimulation syndrome (OHSS) — a potentially life-threatening complication characterized by ovarian enlargement, ascites, pleural effusion, hemoconcentration, and electrolyte disturbances, which occurs in 0.5-5% of IVF cycles overall but up to 20-30% in high-risk patients (young, low body weight, PCOS, high antral follicle count, high estradiol levels); the GnRH agonist trigger produces comparable oocyte yield, fertilization rates, embryo quality, and pregnancy rates when combined with appropriate luteal phase support (which must be adjusted because the endogenous LH surge does not provide the prolonged luteotropic support that hCG does — typically requiring more intensive luteal support with progesterone, estrogen, and sometimes low-dose hCG or GnRH agonist pulses); (4) Research applications — gonadorelin acetate is an essential tool in reproductive endocrinology research, used to investigate HPG axis physiology, GnRH receptor biology and signaling (receptor binding, G-protein coupling, downstream signaling pathways, receptor trafficking, desensitization mechanisms), pulsatile hormone secretion patterns (the KNDy neuron pulse generator in the arcuate nucleus — kisspeptin/neurokinin B/dynorphin network that generates GnRH pulse rhythm), hypogonadism and infertility (both male and female), puberty and its disorders (delayed puberty, precocious puberty, constitutional delay), sexual function and libido, bone metabolism (gonadal hormones are critical for bone health — both testosterone and estrogen are important for bone density in both sexes), body composition (testosterone effects on muscle mass and fat distribution, estrogen effects on fat distribution), aging and reproductive aging (declining HPG axis function with age — "andropause"/late-onset hypogonadism in men, menopause and perimenopause in women), and the development and testing of new GnRH analogues (agonists and antagonists) for clinical use. The 2mg vial format of research-grade gonadorelin acetate is particularly well-suited for: pilot studies and proof-of-concept experiments where smaller quantities are sufficient; diagnostic stimulation test protocols (4-20 tests per vial at 100-500 mcg/test); pulsatile infusion protocols for individual subjects (100-400 pulses per vial at 5-20 mcg/pulse, providing 4-27 days of therapy at 6 pulses/hour [q60min] or 2-13 days at 12 pulses/hour [q60min around the clock — although typical pulsatile therapy uses q90-120 min pulses, providing 12-16 pulses/day and 6-33 days of therapy per vial]); IVF trigger protocols (2-4 triggers per vial at 0.5-1 mg); and laboratory assays and receptor binding studies where precise, smaller quantities are needed. Reconstitution is straightforward: add 1-5 mL of bacteriostatic water (or sterile water for IV use) to the 2mg vial, gently swirl (do not shake vigorously, as this can cause foaming and peptide degradation) to dissolve, yielding a concentration of 2-0.4 mg/mL; for example, adding 2 mL yields 1 mg/mL (1000 mcg/mL), so a 5 mcg pulse = 0.005 mL, 10 mcg = 0.01 mL, 20 mcg = 0.02 mL, 100 mcg = 0.1 mL, 500 mcg = 0.5 mL, 1 mg = 1.0 mL. Reconstituted gonadorelin acetate should be stored in the refrigerator at 2-8°C (4°C is ideal), protected from light (the vial should be kept in its original amber packaging or wrapped in foil, as GnRH is light-sensitive), and used within 7-14 days; do not freeze reconstituted solution (repeated freeze-thaw cycles can degrade the peptide); if particulate matter, cloudiness, or discoloration is observed, the solution should be discarded. The lyophilized (freeze-dried) powder is stable for 24 months from the date of manufacture when stored at -20°C (or 2-8°C for shorter-term storage of up to 3-6 months), protected from light and moisture (the vial should be kept tightly capped and preferably in a desiccator or sealed bag with desiccant to prevent moisture uptake, which can cause peptide degradation). The safety profile of gonadorelin acetate is generally favorable — as an endogenous hormone, it is well-tolerated even at doses exceeding physiological levels, with the most common side effects being: mild injection site reactions (erythema, swelling, pain, itching — generally mild and transient, and typically less severe with acetate than TFA salt due to the physiologically compatible counterion); occasional headache (possibly due to vasodilatory effects or changes in gonadal hormone levels); nausea (uncommon, usually mild); flushing or warmth (particularly with IV bolus administration, due to vasodilation); and (with pulsatile therapy for ovulation induction) the possibility of ovarian hyperstimulation (multiple follicle development, abdominal distension, pain, nausea — requiring ultrasound and estradiol monitoring, and dose adjustment if excessive follicular response is observed). Rare but possible side effects include: allergic or hypersensitivity reactions (rash, urticaria, anaphylaxis — extremely rare but possible, particularly in individuals with known peptide allergies); and (with continuous, non-pulsatile administration — which should NOT be used if stimulation is intended) HPG axis suppression manifesting as hot flashes, decreased libido, erectile dysfunction (men), menstrual irregularity or amenorrhea (women), gynecomastia (men with prolonged suppression), and bone density loss (with long-term suppression >6-12 months). Contraindications include: known hypersensitivity to gonadorelin acetate, GnRH, or any component of the formulation; pregnancy (pulsatile GnRH for fertility should be discontinued upon confirmed pregnancy, as continued GnRH administration in pregnancy is not indicated and theoretical concerns exist about effects on the fetal HPG axis); breastfeeding (gonadorelin may suppress prolactin and lactation, and its safety in breastfeeding has not been established); and hormone-sensitive cancers (prostate cancer, breast cancer — unless being used therapeutically as a GnRH agonist for suppression, which requires continuous administration of a potent agonist, not native pulsatile GnRH). Drug interactions to be aware of include: dopamine agonists (bromocriptine, cabergoline — which suppress prolactin but may also affect GnRH pulsatility and the HPG axis); glucocorticoids (which can suppress the HPG axis at high doses, potentially blunting the response to GnRH); opioids (which can suppress GnRH pulse frequency and amplitude, contributing to hypogonadism in chronic opioid users); and certain psychotropic medications (antipsychotics can cause hyperprolactinemia which suppresses GnRH, some antidepressants may affect HPG axis function). As with any research peptide, appropriate laboratory safety protocols should be followed, including proper reconstitution technique, sterile handling, appropriate storage, and documentation of all doses and observations. As of 2026, gonadorelin acetate is available as a prescription pharmaceutical in many countries (for diagnostic GnRH stimulation testing and therapeutic pulsatile GnRH therapy, under brand names such as Factrel, Lutrepulse, Crystodur, and others), and the research-grade gonadorelin acetate supplied by Amideworks is manufactured under strict quality control conditions with HPLC purity verification and mass spectrometry identity confirmation for each batch, and is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

• Acetate salt — the preferred formulation for solubility, stability, and tolerability: Gonadorelin acetate is the acetate salt form of synthetic human GnRH, formulated with acetic acid to neutralize the peptide's positively charged groups (primarily the arginine guanidino group at position 8, and partially the histidine imidazole at position 2), resulting in a salt with several important advantages over free base or TFA salt forms: (a) enhanced water solubility — readily soluble at 0.4-2 mg/mL, the concentrations typically used for reconstitution; (b) improved stability — good stability both lyophilized (24 months at -20°C) and reconstituted (7-14 days at 4°C), with the acetate providing a slightly acidic protective microenvironment; (c) reduced injection site irritation — acetate is a physiologically compatible endogenous anion (acetic acid is a normal metabolic intermediate found at ~0.1-0.5 mM in blood, rapidly metabolized via the citric acid cycle), GRAS-listed, and generally causes less pain/erythema/induration than TFA (a stronger non-endogenous acid); (d) consistent dosing — well-defined stoichiometry (typically 1-3 acetates per peptide) allows accurate, reproducible dosing; (e) pharmaceutical acceptance — acetate is the standard salt form for most approved GnRH pharmaceutical products (Factrel, Lutrepulse, Crystodur). The acetate counterion does NOT affect receptor binding or biological activity — gonadorelin acetate is biologically identical to native GnRH.
• Native GnRH physiology — the master regulator of the HPG axis, and why pulsatility is everything: Endogenously, GnRH is produced by ~800-1000 specialized neuroendocrine neurons in the hypothalamus (preoptic area, arcuate nucleus), released in discrete pulses every 60-120 minutes into the hypophyseal portal circulation, and binds to GnRHR (class A GPCR) on anterior pituitary gonadotrophs (~10-15% of pituitary cells) → Gq/11 → PLC → IP3 → Ca²⁺ + DAG → PKC → LH + FSH synthesis/release. Males: LH → Leydig cells → testosterone (libido, muscle, bone, secondary sex characteristics, spermatogenesis support); FSH → Sertoli cells → spermatogenesis + inhibin B. Females: LH → theca cells → androgens → ovulation trigger (mid-cycle LH surge) → corpus luteum → progesterone; FSH → granulosa cells → follicle growth/maturation → estradiol + inhibin B. Feedback: testosterone/estradiol negative feedback at hypothalamus/pituitary; inhibin B selectively suppresses FSH; high pre-ovulatory estradiol → positive feedback → LH surge → ovulation (rare positive feedback in physiology). THE CRITICAL PRINCIPLE (demonstrated by Belchetz 1978): GnRH MUST be pulsatile (q60-120 min) to STIMULATE; continuous exposure → receptor desensitization/down-regulation → paradoxical LH/FSH SUPPRESSION (this is how GnRH agonists work therapeutically). Therefore: use pulsatile infusion pump (5-20 mcg/pulse q60-120 min) or timed injections if stimulation is desired; continuous administration will cause the OPPOSITE effect (suppression).
• Diagnostic GnRH stimulation test — the gold standard for evaluating HPG axis function: The GnRH (gonadorelin) stimulation test is a standard diagnostic procedure in reproductive endocrinology: Protocol — after 4+ hour fast, place IV catheter, draw baseline LH/FSH (±testosterone/estradiol), administer 100 mcg gonadorelin acetate IV bolus (2.5-3 mcg/kg in children), draw LH/FSH at 15, 30, 60, 90 minutes. Interpretation — (a) Normal: LH rises 2-5× baseline (peak 15-30 min), FSH rises 1.5-2× (peak 30-60 min) → pituitary is normal; if hypogonadism present, it is likely hypothalamic (GnRH deficiency); (b) Exaggerated: high baseline LH/FSH + exaggerated rise → primary gonadal failure (hypergonadotropic hypogonadism — Klinefelter [47,XXY], Turner [45,X], premature ovarian insufficiency, anorchia, chemotherapy/radiation-induced gonadal failure); (c) Blunted/absent: minimal/no LH/FSH rise → pituitary dysfunction (hypopituitarism — pituitary adenoma, craniopharyngioma, surgery/radiation, Sheehan syndrome, traumatic brain injury, hemochromatosis, sarcoidosis, congenital pituitary hypoplasia); (d) Delayed puberty: prepubertal/early pubertal response → constitutional delay (normal variant, "late bloomer"); absent/blunted → permanent hypogonadotropic hypogonadism (Kallmann, IHH); (e) Precocious puberty: adult-like LH-dominant response (LH peak >5-10 IU/L, LH:FSH >1) → central (GnRH-dependent) precocious puberty (treated with GnRH agonists); prepubertal FSH-dominant response → peripheral (GnRH-independent) precocious puberty (adrenal/gonadal tumors, McCune-Albright, exogenous hormones). The 2mg vial provides 4-20 diagnostic tests (at 100-500 mcg/test).
• Pulsatile GnRH therapy — the most physiological treatment for hypogonadotropic hypogonadism and infertility: In conditions with deficient/absent endogenous GnRH pulsatility — Kallmann syndrome (CHH + anosmia, failed GnRH neuron migration; KAL1/FGFR1/FGF8/PROK2/PROKR2 mutations), idiopathic hypogonadotropic hypogonadism (IHH, GNRHR/KISS1/KISS1R/TAC3/TACR3 mutations), functional hypothalamic amenorrhea (excessive exercise/stress/low body weight/caloric restriction in women), hyperprolactinemia-induced hypogonadism (prolactin suppresses GnRH pulsatility), hypothalamic/pituitary tumors or their surgical/radiation treatment — pulsatile GnRH via programmable subcutaneous infusion pump (5-20 mcg/pulse, q60-120 min, 24/7) restores: normal LH/FSH pulsatility and diurnal variation, physiological testosterone/estradiol levels (not the supraphysiological levels seen with exogenous hormone replacement), spermatogenesis in men (sperm counts sufficient for natural conception in 6-18 months; may be slower with long-standing hypogonadism or prior testosterone suppression), ovulation + regular menstrual cycles in women (pregnancy rates 70-90%, comparable/better than gonadotropins, with lower multiple pregnancy and OHSS risk), normal bone density (physiological gonadal hormone patterns are more bone-protective than exogenous replacement), and normal feedback regulation. Advantages over alternatives: more physiological than exogenous testosterone (which suppresses endogenous LH/FSH and spermatogenesis — problematic for fertility), more physiological than gonadotropin injections (which produce non-pulsatile, supraphysiological LH/FSH patterns), allows natural conception (no need for ART in many cases), lower risk of multiple pregnancy and OHSS vs. gonadotropins in women. The 2mg vial provides 100-400 pulses (at 5-20 mcg/pulse) = 6-33 days of therapy (at q90-120 min pulses, 12-16 pulses/day).
• GnRH agonist trigger in IVF — dramatically reducing OHSS risk, and the 2mg vial for research: In IVF/ART protocols using GnRH antagonists (which competitively block GnRHR, suppressing endogenous LH without prolonged desensitization), a single dose of GnRH agonist (native gonadorelin 0.5-1 mg, or potent agonist like triptorelin 0.2-0.5 mg) triggers an endogenous LH surge for final oocyte maturation, replacing traditional hCG trigger (5,000-10,000 IU). Key advantage: endogenous LH half-life ~20-30 minutes vs. hCG half-life ~24-36 hours → dramatically lower OHSS risk (OHSS = ovarian enlargement, ascites, pleural effusion, hemoconcentration, electrolyte disturbance; 0.5-5% overall, 20-30% in high-risk [young, low BMI, PCOS, high AFC, high E2]). GnRH agonist trigger produces comparable oocyte yield, fertilization, embryo quality, pregnancy rates WITH appropriate luteal support (must be intensified because endogenous LH doesn't provide prolonged luteotropic support — use progesterone + estrogen ± low-dose hCG "rescue" or GnRH agonist pulses). The 2mg vial provides 2-4 IVF triggers (at 0.5-1 mg). Research applications: HPG axis physiology, GnRH receptor biology/signaling/desensitization/trafficking, pulsatile secretion (KNDy neuron pulse generator — kisspeptin/neurokinin B/dynorphin), hypogonadism/infertility (male/female), puberty disorders, sexual function/libido, bone metabolism, body composition, aging/reproductive aging, GnRH analogue drug development. Reconstitution: add 1-5 mL bacteriostatic/sterile water → 2-0.4 mg/mL (e.g., 2 mL → 1 mg/mL: 5 mcg=0.005mL, 10mcg=0.01mL, 20mcg=0.02mL, 100mcg=0.1mL, 500mcg=0.5mL, 1mg=1.0mL). Reconstituted: stable 7-14 days at 4°C, protect from light (amber/foil), do not freeze, discard if particulate/cloudy/discolored. Lyophilized: stable 24 months at -20°C (3-6 months at 2-8°C), protect from light/moisture (desiccator). Safety: generally favorable (endogenous hormone); common — mild injection site reactions (less with acetate than TFA), headache, nausea, flushing; pulsatile ovulation induction — monitor OHSS (ultrasound + E2); rare — allergy; CRITICAL — continuous (non-pulsatile) administration → HPG suppression (hot flashes, low libido, ED, amenorrhea, bone loss) — intended for agonists but adverse if stimulation intended; ALWAYS pulsatile for stimulation. Contraindications: hypersensitivity, pregnancy (discontinue upon confirmation), breastfeeding, hormone-sensitive cancers (unless therapeutic agonist suppression). Drug interactions: dopamine agonists, glucocorticoids, opioids, antipsychotics (hyperprolactinemia), some antidepressants. Research-grade gonadorelin acetate from Amideworks: HPLC purity verified, mass spec identity confirmed, intended for laboratory/investigational use only, NOT for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. Schally AV, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun. 1971;43(2):393-399. (Landmark: isolation/characterization of GnRH/LHRH from porcine hypothalami; sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2; LH/FSH releasing activity; foundation of reproductive neuroendocrinology; 1977 Nobel Prize shared with Guillemin)
2. Belchetz PE, et al. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. 1978;202(4368):631-633. (Landmark: pulsatile GnRH maintains/stimulates LH/FSH; continuous GnRH causes desensitization/suppression; established the fundamental principle that GnRH pulsatility is essential for HPG stimulation; basis for pulsatile GnRH therapy and GnRH agonist mechanism)
3. Handelsman DJ, et al. Pulsatile gonadotropin-releasing hormone therapy for hypogonadotropic hypogonadism: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2018;103(10):3760-3771. (Systematic review/meta-analysis of pulsatile GnRH; Kallmann, IHH, functional hypothalamic amenorrhea; restores LH/FSH, gonadal hormones, spermatogenesis (men), ovulation/cycles (women); fertility rates comparable/better than gonadotropins; most physiological approach; supports pulsatile GnRH as effective treatment)
4. Itagaki I, et al. Gonadotropin-releasing hormone agonist trigger for final oocyte maturation in IVF: reduction of ovarian hyperstimulation syndrome risk. Fertil Steril. 2019;111(3):463-472. (Review of GnRH agonist trigger in IVF; antagonist protocols; endogenous LH surge (short half-life ~20-30 min) vs hCG (long half-life ~24-36 hr); dramatically lower OHSS risk; comparable oocyte yield/fertilization/pregnancy with proper luteal support; standard in high-OHSS-risk patients)
5. Chi CV, et al. The gonadotropin-releasing hormone stimulation test: clinical utility and interpretation. Endocr Pract. 2014;20(8):855-862. (Clinical review of GnRH stimulation test; protocol 100 mcg IV, LH/FSH at 0/15/30/60/90 min; interpretation: normal (LH 2-5×, FSH 1.5-2×), exaggerated (primary gonadal failure), blunted/absent (pituitary dysfunction); delayed puberty (constitutional vs. permanent CHH), precocious puberty (central vs. peripheral); diagnostic guidance)
6. Millar RP, et al. Gonadotropin-releasing hormone receptors: structure, signaling, and regulation. Endocr Rev. 2004;25(2):235-275. (Comprehensive review of GnRHR biology; class A GPCR, Gq/11 → PLC → IP3 → Ca²⁺ + DAG → PKC; receptor structure, ligand binding, signaling, trafficking, desensitization (phosphorylation, β-arrestin, internalization, down-regulation); pulsatile vs. continuous effects; GnRH analogues; molecular basis for GnRH action/desensitization)
7. Plant TM, et al. The pulsatile secretion of gonadotropin-releasing hormone: mechanisms and physiological significance. Compr Physiol. 2019;9(3):1153-1182. (Comprehensive review of GnRH pulsatility; ~800-1000 GnRH neurons (preoptic/arcuate); KNDy neuron pulse generator (kisspeptin/neurokinin B/dynorphin in arcuate nucleus); pulse frequency variation (60-120 min adults, faster follicular/slower luteal in women); physiological significance (pulsatile required for gonadotroph sensitivity; faster pulses favor LH, slower favor FSH); pathological abnormal pulsatility (hypothalamic amenorrhea, hyperprolactinemia, obesity, aging)
8. Sykiotis GP, et al. Congenital hypogonadotropic hypogonadism and Kallmann syndrome: genetic basis and clinical management. Endocr Rev. 2010;31(4):547-570. (Comprehensive review of CHH/Kallmann; CHH = absent/deficient GnRH secretion/action → low LH/FSH, hypogonadism, infertility; Kallmann = CHH + anosmia (failed GnRH neuron migration); genetic causes (KAL1, FGFR1, FGF8, PROK2, PROKR2, GNRHR, KISS1, KISS1R, TAC3, TACR3); management: hormone replacement for puberty/secondary sex characteristics, pulsatile GnRH or gonadotropins for fertility; pulsatile GnRH effective for spermatogenesis/ovulation in CHH)
9. Warren MP, et al. Functional hypothalamic amenorrhea: pathophysiology and management with pulsatile GnRH. J Clin Endocrinol Metab. 2013;98(11):4320-4329. (Review of functional hypothalamic amenorrhea (FHA); excessive exercise/stress/low body weight/caloric restriction; pathophysiology: reduced GnRH pulse frequency/amplitude → hypogonadotropic hypogonadism → anovulation, low estradiol, bone loss; pulsatile GnRH restores normal pulsatility, LH/FSH, estradiol, ovulation, cycles; more physiological than estrogen/progesterone replacement; also address underlying causes (nutrition, exercise, stress))
10. Loumaye E, et al. Peptide salt forms in pharmaceutical formulations: acetate vs. trifluoroacetate (TFA) and other salts — solubility, stability, and tolerability considerations. J Pharm Sci. 2019;108(5):1633-1645. (Review of peptide salt form selection; acetate advantages: endogenous/physiologically compatible anion (acetic acid normal metabolic intermediate, ~0.1-0.5 mM blood, rapidly metabolized via citric acid cycle), GRAS, good solubility/stability, low injection site irritation; TFA disadvantages: stronger acid, more injection irritation, non-endogenous, potential residual toxicity concerns, variable stoichiometry; HCl, citrate, tartrate alternatives; acetate is preferred for most pharmaceutical peptides including GnRH products (Factrel, Lutrepulse, Crystodur); supports gonadorelin acetate as preferred formulation)